PCSK9 Inhibitors for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

PCSK9 Inhibitors for Health & Longevity

Created on 06/30/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

These injectable medicines sharply lower the artery-damaging cholesterol most tied to heart attacks and strokes. For people with existing heart or artery disease, or very high risk, they reliably cut these events; benefit is modest at low risk. Whether they lengthen life remains genuinely unsettled. Main downsides are mild injection-site and cold-like symptoms; high cost limits access. (Full Review)

Protocol

Who
Add-on for high-risk
For high or very-high-risk individuals above their LDL-C target on a maximally tolerated statin (±ezetimibe), or genuinely statin-intolerant.
Dosing
Subcutaneous injection
Evolocumab and alirocumab self-injected every 2 weeks (or higher dose monthly); inclisiran given by a clinician at baseline, 3 months, then every 6 months.
Background statin
Maintain where tolerated
Largest event reductions came on a statin background; continuing a tolerated statin rather than substituting prevents under-treatment.
Time to effect
LDL-C reduction
1–2 weeks
Substantial reductions measurable within about 1–2 weeks of the first antibody dose.
Confirm response
4–8 weeks
Lipid effect confirmable on a follow-up panel at 4–8 weeks.
CV-risk reduction
Months to years
Cardiovascular-risk reduction accrues over months to years.

Benefits

Contraindications
  • Documented serious hypersensitivity (anaphylaxis) to the specific agent
  • Pregnancy and breastfeeding (caution/avoid)
    •
Key Interactions
  • Additive lipid-lowering agents (statins, ezetimibe, bempedoic acid, soluble fiber, red yeast rice, plant sterols)
  • Combining with inclisiran (investigational)
    •

Risk & Side Effects

  • High: Injection-site reactions
    •
  • Medium: Flu-like and cold symptoms / nasopharyngitis
    •
  • Low: Neurocognitive concerns (conflicted); immunogenicity and loss of efficacy
    •
  • Speculative: New-onset diabetes and theoretical effects of very low LDL-C
    •

Monitoring

Marker Target Why
LDL-C Often <55 mg/dL for very-high-risk; many longevity practitioners target lower Primary efficacy target
ApoB <60–80 mg/dL in high-risk, lower for aggressive prevention Best single measure of atherogenic particle burden
Lipoprotein(a) <75 nmol/L (≈<30 mg/dL) Identifies inherited residual risk and potential added benefit
Fasting glucose / HbA1c Glucose <100 mg/dL; HbA1c <5.7% Screen the speculative diabetes concern
ALT / AST Within normal limits General safety and statin-cotreatment context

Cadence: Lipid panel at 4–8 weeks to confirm response, again at 3–6 months, then every 6–12 months once stable. Lipoprotein(a) once; glucose periodically in at-risk users.

Qualitative Assessment

  • Consistency and ease of the injection routine (adherence)
  • Absence of bothersome injection-site or cold-like symptoms
  • Subjective tolerability compared with prior statin experience (relevant in statin-intolerant users)
  • Overall sense of cardiovascular reassurance from reaching target numbers
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.